Abstract
GWAS of Diabetic Nephropathy: Is the GENIE out of the Bottle?
Highlights
New management and treatment approaches are desperately needed and defining the genetic architecture regulating Diabetic nephropathy (DN) would accelerate their development
Family-based linkage and candidate gene analyses as well as the initial genome-wide association studies (GWAS), performed in single studies with limited power, showed inconsistent results in both T1D and T2D patients [8]. In this issue of PLOS Genetics, the GENIE consortium presents results of the largest DN GWAS meta-analysis performed to date
The DN definition essentially mixes two traits, each with distinct underlying pathomechanisms: ESRD as the extreme form of reduced kidney function, and macroalbuminuria reflecting severe glomerular filtration barrier dysfunction. Since these two traits have distinct genetic underpinnings [11,12,13,14,15,16], the authors refined their DN case definition to include only diabetic ESRD patients, which were contrasted with all other diabetic individuals regardless of albumin excretion level
Summary
New management and treatment approaches are desperately needed and defining the genetic architecture regulating DN would accelerate their development. Family-based linkage and candidate gene analyses as well as the initial genome-wide association studies (GWAS), performed in single studies with limited power, showed inconsistent results in both T1D and T2D patients [8].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.